Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Down 26.5% in February

Genenta Science S.p.A. (NASDAQ:GNTA) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 2,500 shares, a decrease of 26.5% from the January 31st total of 3,400 shares. Based on an average daily volume of 10,500 shares, the short-interest ratio is presently 0.2 days.

Genenta Science Stock Performance

Shares of Genenta Science stock opened at $3.90 on Monday. The company’s 50 day moving average is $4.22 and its 200 day moving average is $4.57. Genenta Science has a twelve month low of $2.20 and a twelve month high of $7.28.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genenta Science stock. Citadel Advisors LLC purchased a new position in Genenta Science S.p.A. (NASDAQ:GNTA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 11,167 shares of the company’s stock, valued at approximately $46,000. Citadel Advisors LLC owned 0.06% of Genenta Science at the end of the most recent quarter. 15.13% of the stock is owned by hedge funds and other institutional investors.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.